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Phenotypic heterogeneity in cancer cells is widely observed and is often linked to drug resis-
tance. In several cases, such heterogeneity in drug sensitivity of tumors is driven by stochastic
and reversible acquisition of a drug tolerant phenotype by individual cells even in an isogenic
population. Accumulating evidence further suggests that cell-fate transitions such as the epithelial
to mesenchymal transition (EMT) are associated with drug resistance. In this study, we analyze
stochastic models of phenotypic switching to provide a framework for analyzing cell-fate transitions
such as EMT as a source of phenotypic variability in drug sensitivity. Motivated by our cell-culture
based experimental observations connecting phenotypic switching in EMT and drug resistance,
we analyze a coarse-grained model of phenotypic switching between two states in the presence of
cytotoxic stress from chemotherapy. We derive analytical results for time-dependent probability
distributions that provide insights into the rates of phenotypic switching and characterize initial
phenotypic heterogeneity of cancer cells. The results obtained can also shed light on fundamental
questions relating to adaptation and selection scenarios in tumor response to cytotoxic therapy.
I. INTRODUCTION
Acquisition of drug resistance constitutes a major challenge in cancer therapy [1–13]. Therapeutic agents (with
widely varying biochemical mechanisms) often exhibit a common pattern of providing an initial reduction in tumor
burden followed by recurrence of therapeutically resistant disease with more aggressive progression [6, 11, 12, 14].
Tumor recurrence, which is a major obstacle for cancer cure, is primarily associated with the survival and growth
of cell phenotypes that are resistant to chemotherapy [15–17]. Therefore, in order to develop new strategies for
the effective treatment of human cancers, a quantitative understanding of the underlying processes leading to drug
resistance is essential.
Cellular phenotypic heterogeneity is widely observed in many cancers [3, 5, 8, 18–20] as a tumor is often composed of
multiple subpopulations [21, 22] that show different responses to chemotherapy [9]. In particular, cellular phenotypes
that are not sensitive to drugs survive the treatment and can drive drug resistance. As the underlying processes
that can lead to the emergence of resistant cells are often stochastic, tumors may locally contain varying numbers of
resistant cells. Therefore, quantifying the statistics of drug resistant cells in a tumor is important for effective therapy.
Specifically, we are interested in studying population heterogeneity at the start of therapy and aim to address an
important issue of therapeutic importance, namely, how to quantify randomness in the numbers of resistant cells
prior to drug treatment.
In analyzing population heterogeneity in tumors, a basic question that arises is: How are cell phenotypes that confer
survival advantage in the presence of chemotherapeutic drugs generated? A common explanation for the emergence
of such phenotypes revolves around Darwinian selection of pre-existing cellular heterogeneity that arises due to
random genetic mutations [23–25]. However, the fact that resistant cells switch reversibly to sensitive cells, and that
resistant cells often appear on short time intervals (hours to few days), starting from clonal populations, suggests
that non-genetic factors play a major role in the generation of phenotypic heterogeneity [5, 7, 13, 26–30]. Such
non-genetic phenotypic heterogeneity can arise due to multistability in the underlying gene expression dynamics
[31, 32] and noise in gene expression[33].
These observations suggest that there are two distinct, though not mutually exclusive, mechanisms for the onset of
drug resistance in cancer cells: 1) cell phenotypes that are resistant to chemotherapy pre-exist in the tumor prior to
treatment and are selected for during the treatment, and 2) cells are induced to develop or acquire resistance due
to treatment. In the literature, the former scenario is termed selection while later corresponds to adaptation. This
adaptation-selection scenario was first explored in the famous Luria-Delbru¨ck experiments [34] to understand the
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2mechanism of bacterial resistance to bacteriophage infections. The corresponding analysis gave rise to the celebrated
fluctuation test which is also used to estimate mutation rates in bacteria. It is important to note that, while in
the Luria-Delbru¨ck case phenotypic changes are driven by genetic mutations and thus an irreversible process, in
our study, we are considering phenotypic changes that are reversible. Besides reversible phenotypic switching, it is
important to consider intrinsic stochasticity in the underlying processes and to characterize cellular heterogeneity as
highlighted by previous studies focusing on modeling drug resistance in cancer [35, 36].
In consideration of cellular mechanisms likely to be associated with drug resistance, the epithelial-mesenchymal
transition (EMT) emerges as a logical candidate. EMT is a conserved cellular program that enables cells of epithelial
lineage to transiently acquire traits of mesenchymal cells, including reversible loss of adherens junctions and gain of
proteins associated with enhanced motility, adhesion to extracellular substrates and remodeling of the extracellular
matrix [37, 38]. In cancer cells, this ability to reversibly adopt a more motile phenotype has been linked to tumor
invasion and metastasis [39–41] but, more importantly for this study, EMT is also directly linked to chemotherapy
resistance and cancer stem cell (CSC) properties [42, 43]. In the context of this background, experimental studies
described herein focus on established markers of epithelial and mesenchymal phenotype in relation to chemotherapy
response, which in this report involves pancreatic ductal adenocarcinoma (PDAC) cells. While recognizing that
EMT is more likely a spectrum of intermediate states [44–48], the strong correlation in phenotype and drug response
reported here motivates the adoption of two coarse-grained states to be used in the model development. Specifically,
a relatively drug-sensitive state with more pronounced epithelial characteristics (E); and a drug-resistant state with
increased mesenchymal characteristics (M). In the following sections, we will consider these phenotypes to form the
basis of a two-state model of the dynamics of phenotypic switching and associated survival of cancer cells under
cytotoxic stress[22, 26].
The paper is organized as follows. In Section II, a set of motivating experiments is described, in which drug resistance is
evaluated as a determinant of phenotype in pancreatic cancer cells in vitro, and conversely, phenotype as a determinant
of drug response in the same cells. Motivated by these studies, a two phenotype switching model is described in Sec
III. An analytic approach to quantify population heterogeneity at the start of therapy is presented in the Sec IV.
Then, a protocol for estimating switching parameters is presented in Sec V. In Sec VI, we present an approximate
approach for characterizing the probability distribution of the fraction of resistant cells in a population followed by
conclusions presented in Sec VII.
II. EVALUATION OF DRUG RESISTANCE AND PHENOTYPE IN CELL CULTURE STUDIES
We first sought to compare phenotypic traits in naive and drug-resistant pancreatic ductal adenocarcinoma (PDAC)
cells. PANC1 cells (a quasimesnchymal PDAC cell line [49]) were exposed to increasing doses of oxaliplatin chemother-
apy over successive passages until resistant cells were stable through multiple passages and cryopreservation. As shown
in Figure 1 (upper panels), acquisition of chemoresistance leads to a marked change in phenotype from naive cells
displaying characteristically epithelial adherens junctions, to drug-resistant cells with highly branched morphology,
no evident E-cadherin, and marked increase in cytoskeletal vimentin (IF quantification, upper right). This pattern of
changes in E-cadherin and vimentin expression are classic and well-established markers of EMT. We further examined
the reciprocal scenario, in which the same parental cells were directly induced [37]to undergo EMT via adminis-
tration of exogenous TGF-β (Figure 1, lower panels). The resultant phenotype is strikingly similar to that of our
drug-resistant cells and importantly, exhibits resistance to chemotherapy similar to when resistance was acquired
directly through drug exposure. Collectively these results display a symmetry in that acquisition of drug resistance
in epithelial cancer cells leads to increase in mesenchymal characteristics, while direct transition from epithelial to
mesenchymal phenotype leads to drug resistance.
Methods
Cell culture and reagents: PANC1 cells were obtained from the American Type Culture Collection (Manassas,
VA), and grown in T-75 cell culture flasks according to ATCC guidelines. DMEM medium (HyClone; Logan, UT)
was supplemented with 10% FBS (HyClone; Logan, UT), 100 IU/mL penicillin and 1% streptomycin (HyClone;
Logan, UT), and 0.5 ug/mL Amphotericin B (Corning; Corning, NY). The drug-resistant subline, PANC1-OR was
generated as described previously [53]. Briefly, increasing concentrations of oxaliplatin were added to each cell
type in regular media over the course of approximately 25 passages until a stable proliferative phenotype without
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FIG. 1: Equivalence in the acquisition of chemotherapy resistance and epithelial-mesenchymal transition in pancreatic cancer
cells.
chemotherapy was observed and maintained following cryopreservation and confirmed by comparative dose response
and measurement of a statistically significant increase in IC50.
Immunofluorescence sample preparation and imaging: Formaldehyde-fixed cells in optical-bottom multiwell
plates were incubated overnight at 4◦C with primary antibodies against e-cadherin and vimentin (Cell Signaling
EMT Duplex; Danvers, MA). After washing with PBS, cells were incubated for 1 hour with mouse or rabbit Alexa
Fluor secondary antibodies (Cell Signaling; Danvers, MA). Cells were mounted with ProLong Gold Antifade reagent
containing DAPI (ThermoFisher Scientific Molecular Probes; Waltham, MA) and imaged after 24 hours using a
Zeiss LSM 880 confocal microscope with the same detector settings and excitation laser power settings across groups.
Images were analyzed using custom Matlab scripts where fluorescent signal for each protein was normalized to the
number of cells based on DAPI-stained nuclei.
Therapeutic response assessment: In sample wells receiving chemotherapy treatment, oxaliplatin (Selleck
Chemical; Houston, TX) was added to the media at doses ranging from 0.1 to 500 µM for 48 hours. In experiments
where EMT was induced via TGF-beta, 10 ng/mL human recombinant TGF-beta (Gibco, Thermo Fisher Scientific)
in 1% FBS DMEM was added to designated wells for 48 hours and respective comparison groups were also grown in
1% FBS for the same duration. In all therapeutic studies treatment conditions were prepared in at least triplicate
within each batch including internal controls with sham manipulations. Therapeutic response was assessed via the
CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega; Madison, WI) at 490nm absorbance in a
BioTek Epoch Microplate Spectrophotometer.
III. COARSE-GRAINED MODEL
Motivated by the preceding observations and by previous work [22, 26], we now consider a simple coarse-grained
model (Fig. 2) for phenotypic heterogeneity in tumor cells. We consider that the population of cancer cells consists
of two distinct subpopulations; drug-sensitive or drug-tolerant. Based on our experimental results, we denote the
drug-sensitive population by E (for epithelial phenotype) and the drug-tolerant population by M (for mesenchymal
phenotype). The processes that control the evolution of tumor heterogeneity are as follows: 1) birth: each E-type
or M -type cell gives rise to birth of new cells of the same type with rates kE and kM , respectively; 2) death: each
E-type (M -type) cell degrades with rates µE (µM ); 3) phenotypic switching : an E cell can switch to a M cell with
4rate kEM , and M cell can switch back to E cell with rate kME .
At any time t, the state of the system is defined by the number of E and M cells. The temporal evolution of the
corresponding probability distribution is given by the master equation:
∂P (E,M, t)
∂t
= kE(E − 1)P (E − 1,M, t) + kM (M − 1)P (E,M − 1, t)
+ µE(E + 1)P (E + 1,M, t) + µM (M + 1)P (E,M + 1, t)
+ kME(M + 1)P (E − 1,M + 1, t) + kEM (E + 1)P (E + 1,M − 1, t)
− [kEE + kMM + µEE + µMM + kMEM + kEME]P (E,M, t), (1)
where P (E,M, t) denotes the probability that there are E and M numbers of epithelial and messenchymal cells
present at time t.
kMkE
μMμE
kEM
kME
FIG. 2: Schematic representation of the two phenotype EMT model of tumor growth: Sensitive and resistant phenotypes are
shown as green and red circles respectively. The phenotypic switching rates are represented by KEM and KME , birth rates by
kE and kM , and death rates by µE and µM .
Within the framework of this model (Fig. 2), we now address a key issue: How to characterize the initial heterogeneity
(i.e. prior to the start of drug exposure) in tumor cells. To quantify this heterogeneity, let us consider the fraction
of M - cells in the population. Consider the case that we isolate different sample populations from the tumor each
corresponding to a fixed number (N0) of cells, see Fig. 3. Let p0 = M/N0 denote the fraction of M -cells in the
sample population. We propose to quantify tumor heterogeneity by considering p0 as a random variable drawn from
a distribution ρ(p0), characterized by its mean 〈p0〉 and variance σ2p0 = 〈p20〉−〈p0〉2. Thus, initial tumor heterogeneity
is characterized not just by the presence of drug-tolerant M cells in the sample but also by variations in the number
of M cells from sample to sample, characterized by the distribution ρ(p0).
IV. ANALYTICAL RESULTS FOR PARAMETER ESTIMATION
We now consider the stochastic process governing evolution of the tumor population upon treatment with drugs.
Upon exposure to drugs, it is a reasonable assumption that growth is inhibited, so accordingly we set kE = kM = 0.
As discussed in the preceding section, we consider the evolution of different sample populations, each of which has
a fixed initial size N0 such that the fraction of M cells is drawn from a distribution ρ(p0). In this limit, the key
parameters of the model are: kEM , kME , µE , µM , 〈p0〉, σ2p0 . In what follows, we derive analytical results that can be
used to estimate model parameters by analyzing the distribution of surviving cells upon drug exposure.
We note that, within our model, the evolution of each cell in the population is independent of the state of the remaining
cells. Correspondingly, we first focus on the time evolution of a single tumor cell, which is initially either E-type or M -
type with corresponding probabilities as 1−p0 and p0, Let us denote by PE(PM ) the probability that the cell is E(M)-
type at time t, conditional on the initial probability p0 for it to be M -type . The corresponding probability generating
function for the single cell, conditional on the value of p0 (g(z1, z2, t|p0) =
∑
ηE
∑
ηM
zηE1 z
ηM
2 P (ηE , ηM , t|p0)), can be
5p0 = 3/10
p0 = 1/10
p0 = 2/10
p0 = 5/10
p0 = 4/10
p0 = 6/10
p0 = 7/10
p0 = 0
FIG. 3: Schematic representation of tumor containing drug-sensitive (green circles) and drug-resistant cells (red circles) is
shown at the center. For the sake of conceptual visualization, we have shown different samples taken from the tumor, each
characterized by the same number of total cells (here N0 = 10) but different number of M-cells, and thus different values for
p0 = M/N0.
expressed as
g(z1, z2, t|p0) = 1− (PE + PM ) + PEz1 + PMz2. (2)
It is straightforward to derive analytic expressions for PE(PM ) and to thereby obtain an expression for g(z1, z2, t|p0)
(Supplementary Material A). Now, let G(z1, z2, t) denote the probability generating function corresponding to
P (E,M, t), the probability that we have E and M number of sensitive (E-type) and resistant (M -type) cells in
the entire population at time t. Since each cell in the population (initial size N0) evolves independently, the proba-
bility generating function for the joint distribution at time t (averaging over the initial choice of p0) is given by
G(z1, z2, t) =
∫ p0=1
p0=0
dp0ρ(p0)g(z1, z2, t|p0)N0 , (3)
where ρ(p0) is the probability distribution function for the initial fraction of M -type cells (p0).
The expression derived for the generating function, Eq. (3), can be used to derive analytic expressions for all the
moments of the marginal distributions corresponding to E-type and M -type cells at time t. For example, expressions
for mean number of E and M cells can be obtained using 〈E〉 = dG/dz1|z1=1,z2=1and〈M〉 = dG/dz2|z1=1,z2=1,
respectively (see Supplementary Material A). This leads to the following expression for mean number of surviving
cells at time t, 〈N〉 = 〈E +M〉:
〈N〉/N0 =
(
γ0 + α0 − 2(γ0 − µE + µEp0 − µMp0)
2α0
)
exp
(
− t
2
(γ0 + α0)
)
−
(
γ0 − α0 − 2(γ0 − µE + µEp0 − µMp0)
2α0
)
exp
(
− t
2
(γ0 − α0)
)
, (4)
where
γ0 = kEM + kME + µE + µM , α0 =
√
γ20 − 4 (kME(µE − µM ) + (γ0 − µM )µM ). (5)
6It is clear from the above expression that by fitting the curve corresponding to the mean number of surviving cells
as a function of time, the three parameter combinations: α0, γ0, and µE − µEp0 + µMp0 can be determined.
To extract the remaining model parameters based on time-course data, we have to turn to analytic results for the
higher moments. For example, we can use expressions for the Fano factor (F ) associated with total number of surviving
cells, which is given by F = σ2N/〈N〉 with σ2N = 〈N2〉 − 〈N〉2 denoting the variance in the number of surviving cells.
The expression for σ2N can be obtained using
σ2N = σ
2
E + σ
2
M + 2CEM , (6)
where σ2E = 〈E2〉 − 〈E〉2 and σ2M = 〈M2〉 − 〈M〉2 are variances associated with the marginal distributions for the
E and M cells respectively, and CEM = 〈EM〉 − 〈E〉〈M〉 is the correlation between numbers of E and M cells. We
obtain an explicit expression for the Fano factor given by (see Supplementary Material A):
F = 1− 〈N〉
N0
+
N0(N0 − 1)
〈N〉
[(
(µE − µM )
α0
)(
exp
(
− t
2
(γ0 − α0)
)
− exp
(
− t
2
(γ0 + α0)
))]2
σ2p0 . (7)
The Fano factor F is a measure of deviations from the Poisson distribution, for which F = 1. If F < 1 or F > 1,
the distribution is sub-Poissonian or super-Poissonian, respectively. Before turning our attention to approaches for
parameter estimation, let us first examine the expression derived for the Fano factor. We note that in the absence
of initial variability in the fraction of M cells (i.e. σ2p0 = 0), the Fano factor of surviving population is simply given
by F = 1− 〈N〉/N0. As the cells are not dividing due to the exposure to drugs, the mean number of surviving cells
(〈N〉) is less than the initial population of cells (N0) for t > 0. Thus, in this case, the Fano factor is always less
than one and the distribution of cell population follows a sub-Poissonian distribution. However, given variability in
the fraction of M -cells in the initial population, the Fano factor can potentially exceed one making the distribution
super-Poissonian. This result implies that the observation of a Fano factor in excess of 1 in the distribution of
surviving cells is an indicator of variance in the fraction of M -cells in the initial population. Thus the measurements
of the moments of surviving cell populations can provide evidence for phenotypic heterogeneity in tumor populations
prior to drug treatment.
To gain more quantitative insight into the initial heterogeneity, we need to estimate the parameters characterizing
the mean and variance of ρ(p0). Let us rewrite Eq. (7) in a more compact form by regrouping terms in the expression
to yield the following form
F =
(
σp0(µE − µM )
α0
)(
exp
(
t
2
(γ0 − α0)
)
− exp
(
t
2
(γ0 + α0)
))
, (8)
with
F = exp
 ln
((
F − 1 + 〈N〉N0
)
〈N〉
N0(N0−1)
)
2
 . (9)
Using the expressions for the mean and Fano factor of the surviving population as functions of time, Eqs. (4) and
(8), we can estimate four of the parameter combinations, namely, α0, γ0, µE−µEp0 +µMp0, and (σp0(µE−µM ))/α0.
Correspondingly, we need additional experiments to determine the entire set of 6 model parameters. As we now
show, a set of measurements that accomplish this can be obtained by starting from different initial conditions.
The proposed protocol is motivated by that fact that experimental techniques such as fluorescence-activated cell
sorting (FACS) can be used to prepare the samples in specified initial states. With this in mind, we begin from an
initial condition where all cells are E-type i.e. p0 = 0, σ
2
p0 = 0. Using the derived results, we can determine the
parameters µE , α0 and γ0. We next consider the initial condition to be all M -type cells i.e. p0 = 1, σ
2
p0 = 0. Analysis
of the corresponding time-course measurements of the number of surviving cells can now be used to estimate the
parameter µM . Having estimated values of α0, γ0, µE , and µM , we can now find the switching rates, kEM and kME ,
from Eq.(5). Finally, using the expressions for the mean number of surviving cells and corresponding Fano factors for
arbitrary p0, we can get explicit expressions for the probability p0 and variance σ
2
p0 (Supplementary Material A):
p0 =
〈N〉 − 〈N〉0
〈N〉1 − 〈N〉0 ,
σ2p0 =
N0〈N〉
(〈N〉1 − 〈N〉0)2(N0 − 1)
[
F − 1 + 〈N〉
N0
]
. (10)
7The above results are expressed in terms of experimentally measurable quantities, involving mean values 〈N〉0 (for
p0 = 0) and 〈N〉1 (for p0 = 1) and the Fano-factor of the total surviving population, and thus can be used to estimate
the population heterogeneity at the start of drug exposure based on time-course measurements of the surviving
population size.
V. MODELING GENERATION OF TUMOR HETEROGENEITY
The analysis in the preceding section holds regardless of the source of initial heterogeneity in tumor populations.
In this section, we explore how the model introduced for tumor cell dynamics can also be used to analyze a potential
mechanism for generation of tumor heterogeneity. We note that the proposed model in Fig. 2 can be seen as a
generalized version of the celebrated Luria-Delbru¨ck (LD) model with the important addition that, in the present
case, the transition between the two phenotypes is reversible (as opposed to the Luria-Delbru¨ck case). However, while
the LD model can be solved exactly [50], the exact analytical solution of the reversible model in Fig. 2 is not known,
to the best of our knowledge. Nevertheless, as we show below, exact expressions for the mean and variance of the
number of E-type and M -type cells can be obtained and used to characterize heterogeneity in tumor cell populations.
We can use the master equation, Eq.(1), to derive expressions for the mean number of E and M cells at any time t
(Supplementary Material B). Using these expressions, the mean number of surviving cells 〈N〉 = 〈E〉+ 〈M〉 is given
by:
〈N〉 =
(
E0(α− γ − 2kfE) +M0(α− γ − 2kfM )
2α
)
exp
(
− t
2
(γ + α)
)
+
(
E0(α+ γ + 2k
f
E) +M0(α+ γ + 2k
f
M )
2α
)
exp
(
− t
2
(γ − α)
)
, (11)
where
γ = kEM + kME − kfE − kfM , α =
√
γ2 + 4
(
kME(k
f
E − kfM ) + (γ + kfM )kfM
)
,
(12)
with kfE = kE−µE and kfM = kM −µM representing the effective birth rates for E-type and M -type cells respectively,
while E0 and M0 are the initial numbers of E and M cells at t = 0.
The results show that the mean number of surviving cells at any time t is characterized by six parameters: initial
number of E and M cells (E0,M0), two effective birth rates (k
f
E , k
f
M ) and two switching rates (kEM , kME). Given
that the initial population can be chosen in a controlled manner, we can use the results for the mean population size
to determine some of the model parameters. Specifically, we can set M0 = 0 as the initial condition and fitting the
data to obtain the coefficient of exponential terms in Eq. (11) will yield kfE . Next, we can set E0 = 0 and Eq. (11)
will allow us to extract kfM . Once we estimate k
f
E and k
f
M , we can extract the switching rates using the estimated
values of γ and α, using Eq. (12). That is, the proposed procedure allows us to estimate the parameter combinations,
kfE and k
f
M as well as the parameters kEM and kME .
In order to estimate the remaining model parameters, we need to consider the higher moments. While obtaining
analytical expressions for the full probability distribution is still an open problem, higher moments can be calculated
in a straightforward manner. For example, using Eq. (1) the evolution equation for 〈E2〉 = ∑E2P (E,M, t),
〈M2〉 = ∑M2P (E,M, t) and 〈EM〉 = ∑EMP (E,M, t) is given by
∂〈E2〉
∂t
= (kE + µE + kEM )〈E〉+ kME〈M〉+ 2(kE − µE − kEM )〈E2〉+ 2kME〈ME〉,
∂〈M2〉
∂t
= (kM + µM + kME)〈M〉+ kEM 〈E〉+ 2(kM − µM − kME)〈M2〉+ 2kEM 〈ME〉,
∂〈ME〉
∂t
= −kME〈M〉 − kEM 〈E〉+ (kE + kM − µE − µM − kME − kEM )〈ME〉+ kME〈M2〉+ kEM 〈E2〉. (13)
The above set of equations can be solved to get explicit expressions for 〈E2〉, 〈M2〉 and 〈EM〉 at any time t
(Supplementary Material B), which can be used to get the variance (σ2N ) in the total number of surviving cells by
8using Eq. (6). The analytic expression for the variance, in combination with the expression for mean number of
surviving cells, can be used to extract all model parameters. Furthermore, the extracted parameters can then be
compared with the parameters derived based on tumor cell dynamics after exposure to drugs. The comparisons
can provide insight into the relative roles of adaptation and selection in driving tumor heterogeneity. The scenario
wherein the switching parameters kEM and kME are effectively unchanged upon exposure to drugs, whereas µE
and µM increase favors selection as the dominant driver of tumor heterogeneity. However, significant changes in the
switching rates kEM and kME are indicative of a role for adaptation as well in the generation of tumor heterogeneity.
VI. CHARACTERIZING THE DISTRIBUTION OF THE FRACTION OF RESISTANT CELLS
The results derived for the moments can also be used to characterize the probability distribution ρ(p0) for the fraction
of M -type cells. Recall that we must have 0 ≤ p0 ≤ 1 and furthermore the first two moments of ρ(p0) can be obtained
using the procedure outlined in the previous section. Thus a natural choice to characterize the distribution ρ(p0) is to
take it to be the Beta distribution with the mean and variance as determined by measurements. Such a distribution
is expressed in terms of two exponents (α and β) as
ρ(p0) =
Γ(α+ β)
Γ(α)Γ(β)
pα−10 (1− p0)β−1 (14)
with mean 〈p0〉 = αα+β and variance σ2p0 = αβ(α+β)2(α+β+1) . The two parameters of the Beta distribution can be
estimated using the experimentally determined mean and variance. Explicitly, these are given by
α =
〈p0〉
(〈p0〉(1− 〈p0〉)− σ2p0)
σ2p0
, β =
(〈p0〉 − 1)
[〈p0〉2 − 〈p0〉+ σ2p0]
σ2p0
. (15)
To test this approach for characterizing the initial heterogeneity, we compare the Beta distribution with the results
obtained from stochastic simulations of the model. Specifically, we carried out stochastic simulations using the
Gillespie algorithm [51] for the model in Fig.2 starting with 200 sensitive E-type cells and no resistant M-type
cells. The empirically determined distribution for the fraction of M -type cells (ρ(p0)) is then compared to the Beta
distribution with the same mean and variance as the empirical distribution. The results obtained are shown in Fig. 4,
which indicate that the Beta distribution is an excellent approximation for the range of parameters explored.
VII. DISCUSSION
To summarize, we have studied a coarse-grained stochastic model to quantify phenotypic heterogeneity in a population
of cancer cells. Motivated by the experimental observation that both chemoresistance and TGF-β induced EMT lead
to similar outcomes, the model assumes that a cell has two phenotypes corresponding to whether it is drug-sensitive
or drug-resistant. Importantly, the model is also consistent with epigenetic mechanisms for generating phenotypic
heterogeneity in cancer, given that it allows reversible phenotypic switching between sensitive and resistant cells.
For the model considered, we have derived analytic results, both in the presence and absence of chemotherapeutic
agents, which provide insights into the role of phenotypic switching in generating population heterogeneity. One of
the issues that we address through these results focuses on quantifying initial heterogeneity in the fraction of resistant
cells, characterized by mean fraction of resistant cells 〈p0〉 in a tumor and its variance σ2p0 . For this, we propose a
protocol that can be used to estimate the model parameters based on measurements of mean and variance of the
surviving population of tumor cells. Furthermore, our analysis also leads to a condition, in terms of experimentally
measurable quantities, whose value serves as an indicator for the presence of initial heterogeneity in the fraction of
resistant cells.
While the proposed method allows us to estimate the mean and variance of the fraction of resistant cells prior
to therapy, obtaining an exact analytical form for the entire distribution appears to be challenging. However,
our simulation results suggest that this distribution is well approximated by the Beta distribution, which can be
characterized by using the mean and variance of the surviving population. Besides characterizing initial heterogeneity
in the cancer cell population, the estimated model parameters can also be useful in analyzing the complex roles
of adaptation and selection in the acquisition of chemoresistance. Furthermore, the results obtained provide exact
90.01 0.05 0.1
0
5
10
15
20
25
p0
ρ
(p
0
)
0.05 0.1 0.15
0
5
10
15
p0
ρ
(p
0
)
0. 0.07 0.14 0.21
0
3
6
9
12
p0
ρ
(p
0
)
0. 0.07 0.14 0.21 0.28
0
2
4
6
8
p0
ρ
(p
0
)
0.02 0.06 0.1 0.14
0
5
10
15
20
p0
ρ
(p
0
)
0.25 0.35 0.45 0.55
0
3
6
9
p0
ρ
(p
0
)
0.4 0.5 0.6 0.7
0
2
4
6
8
p0
ρ
(p
0
)
0.2 0.4 0.6 0.8
0
1
2
3
4
5
p0
ρ
(p
0
)
0.02 0.08 0.14
0
5
10
15
20
p0
ρ
(p
0
)
0.4 0.52 0.64
0
2
4
6
8
10
p0
ρ
(p
0
)
0.8 0.89 0.98
0
4
8
12
p0
ρ
(p
0
)
0.8 0.89 0.98
0
5
10
p0
ρ
(p
0
)
b)
c)
a)
FIG. 4: Simulation results for the distributions of fraction of M-cells ρ(p0) are shown as histograms and the continuous solid
lines represent fits by Beta distributions. Top (a), middle (b) and lower(c) panels corresponds to kEM/kME=0.1, 1 and 10
respectively. In each panel, distributions are shown at various time points, t = 0.1, 1, 10, 20 from left to right. Other parameters
are: kE = 0.2, kM = 0.1, µE = 0.3, µM = 0.15.
analytical expressions characterizing the distribution of of tumor cell population under treatment by drugs. Going
forward we envision further model development in dialog with experiments that longitudinally monitor phenotypic
changes in time lapse microscopy studies, either by quantitative analysis of morphometric parameters or implementing
fluorescent reporters of EMT which have been recently developed [52]. These results can serve as important inputs
to future work focusing on evaluation of the hypothesis that model-informed design of treatment schedule and dose
parameters may reduce the emergence of chemoresistance.
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Supplementary Material
Supplementary Material A: Analytical results for surviving population upon exposure to drugs
Derivation of single cell generating function
Consider a single cell that can exist either as an epithelial(E) or mesenchymal(M) cell. The rates of switching
between these two phenotypes (E and M) are given by kEM and kME and the rates of cell death are given by µE
and µM , respectively. Here we assume no cell divisions (i.e no new production of cells) for either E or M due to
high levels of external drugs. For such a system, we consider first the temporal evolution of a single cell, given the
initial probability p0 of the cell being M -type. The corresponding probability generating function is g(z1, z2, t|p0)
=
∑
ηE
∑
ηM
zηE1 z
ηM
2 P (ηE , ηM , t|p0), where ηE and ηM can have values 0 or 1, and P (ηE , ηM , t|p0) is the probability
of having ηE and ηM number of cells at time t, given the initial proability p0 of the cell being M -type. Clearly
P (1, 1, t|p0) = 0 since we are starting with a single cell and no new cells are created. Correspondingly at any time t,
we have only three possibilities, either ηE = 1 and ηM = 0 or ηE = 0 and ηM = 1 or ηE = ηM = 0. Thus we obtain
g(z1, z2, t|p0) = P (0, 0, t|p0) + z1P (1, 0, t|p0) + z2P (0, 1, t|p0). (A1)
Denote P (1, 0, t|p0) = PE(t), P (0, 1, t|p0) = PM (t) and P (0, 0, t|p0) = P0(t), and then using the normalization con-
dition, PE(t)+PM (t)+P0(t) = 1, we obtain the single particle generating function as derived in the main text, Eq. (2).
To find an explicit expression for the single cell generating function g(z1, z2, t|p0), we need to find expressions for
the probabilities PE(t) and PM (t). For this, we begin from their evolution equations:
dPE(t)
dt
= kMEPM (t)− (µE + kEM )PM (t),
dPM (t)
dt
= kEMPE(t)− (µM + kME)PM (t).
(A2)
These equations can be solved to give the following expressions for the temporal evolution of the probabilities:
PE =
[
(1− p0)(γ0 + α0 − 2µM )− 2kME
2α
]
exp
(
− t
2
(γ0 + α0)
)
−
[
(1− p0)(γ0 − α0 − 2µM )− 2kME
2α
]
exp
(
− t
2
(γ0 − α0)
)
,
PM =
[
p0(γ0 + α0 − 2µE)− 2kEM
2α
]
exp
(
− t
2
(γ0 + α0)
)
−
[
p0(γ0 − α0 − 2µE)− 2kEM
2α
]
exp
(
− t
2
(γ0 − α0)
)
, (A3)
where α0 and γ0 denote combinations of the model parameters, as given in Eq.(5) in the main text and
p0 = PM (t = 0) as discussed above. Using the expressions for PE and PM from Eq. (A3) in Eq. (2), we obtain the
single particle probability generating function.
Derivation of mean and Fano factor for surviving population
Here we provide the details for the derivation of expressions for temporal evolution of moments associated with
total surviving population. For this, we start from the expression for the generating function,
G(z1, z2, t) =
∞∑
E=0
∞∑
M=0
zE1 z
M
2 P (E,M, t) =
∫ p0=1
p0=0
dp0ρ(p0) [g(z1, z2, t)]
N0 , (A4)
and using Eqs.(A4), (2), (A3) and denoting 〈p0〉 =
∫
p0ρ(p0)dp0 as the mean value of p0, arrive at the following
expressions for the mean numbers of epithelial and mesenchymal cells,
〈E〉 = dG
dz1
∣∣∣∣
1,1
= N0(S0 + S1〈p0〉),
〈M〉 = 〈M〉 = dG
dz2
∣∣∣∣
1,1
= N0(Q0 +Q1〈p0〉),
(A5)
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where
Q0 =
(−2kEM
2α0
)(
exp
(
− t
2
(γ0 + α0)
)
− exp
(
− t
2
(γ0 − α0)
))
,
Q1 =
(
γ0 + α0 − 2µE
2α0
)
exp
(
− t
2
(γ0 + α0)
)
−
(
γ0 − α0 − 2µE
2α0
)
exp
(
− t
2
(γ0 − α0)
)
,
S0 =
(
γ0 + α0 − 2(kME + µM )
2α0
)
exp
(
− t
2
(γ0 + α0)
)
−
(
γ0 − α0 − 2(kME + µM )
2α0
)
exp
(
− t
2
(γ0 − α0)
)
,
S1 =
(
γ0 − α0 − 2µM
2α0
)
exp
(
− t
2
(γ0 − α0)
)
−
(
γ0 + α0 − 2µM
2α0
)
exp
(
− t
2
(γ0 + α0)
)
, (A6)
and α0 and γ0 are given by Eq. (5) in the main text. Using Eq.(A5), we see that the mean number of total surviving
cells (E +M) is given by
〈N〉 = N0 [Q0 + S0 + (Q1 + S1)〈p0〉] . (A7)
We turn next to the second moment and, using the same generating function, the variances in E and M cells are
given by
σ2E =
d2G
dz21
∣∣∣∣
1,1
−
(
dG
dz1
∣∣∣∣
1,1
)2
+
dG
dz1
∣∣∣∣
1,1
,
σ2M =
d2G
dz22
∣∣∣∣
1,1
−
(
dG
dz2
∣∣∣∣
1,1
)2
+
dG
dz2
∣∣∣∣
1,1
, (A8)
leading to the following expression for the Fano factor:
FE =
σ2E
〈E〉 = 1−
〈E〉
N0
+
N0(N0 − 1)
〈E〉 S
2
1σ
2
p0 ,
FM =
σ2M
〈M〉 = 1−
〈M〉
N0
+
N0(N0 − 1)
〈M〉 Q
2
1σ
2
p0 . (A9)
Substituting the expressions for S1 and Q1 and simplifying these Fano factors can be reexpressed as
FE = 1− 〈E〉
N0
+
N0(N0 − 1)
〈E〉
[(
γ0 − α0 − 2µM
2α0
)
exp
(
− t
2
(γ0 − α0)
)
−
(
γ0 + α0 − 2µM
2α0
)
exp
(
− t
2
(γ0 + α0)
)]2
σ2p0 ,
FM = 1− 〈M〉
N0
+
N0(N0 − 1)
〈M〉
[(
γ0 + α0 − 2µM
2α0
)
exp
(
− t
2
(γ0 + α0)
)
−
(
γ0 − α0 − 2µM
2α0
)
exp
(
− t
2
(γ0 − α0)
)]2
σ2p0 .
(A10)
Note that both the Fano factors, FE and FM , are always less than one if σ
2
p0 = 0. That is, a Fano factor greater than
1 is an indication of the presence of initial variability in the fraction of M cells in the population.
To derive an expression for the variance of the total population N = E +M , we use the relation σ2N = σ
2
E + σ
2
M +
2CEM , where CEM = 〈EM〉 − 〈E〉〈M〉 is the correlation between E and M , and 〈EM〉, in terms of the generating
function, is
〈EM〉 = d
dz1
(
dG
dz2
)∣∣∣∣
1,1
. (A11)
The expression for the Fano factor for the total population N can be written as
F = 1− 〈N〉
N0
+
N0(N0 − 1)
〈N〉 (S1 +Q1)
2σ2p0 , (A12)
which, on using Eq. (A6), can be rewritten as Eq. (7) in the main text.
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Expressions for p0 and σ
2
p0
As discussed in the main text, we propose a three-step procedure. First, we set p0 = 0, which, using Eqs. (A7) and
(A12), gives
〈N〉0 = N0(Q0 + S0),
F0 = 1− (Q0 + S0), (A13)
and next, setting p0 = 1,
〈N〉1 = N0(Q0 + S0 +Q1 + S1),
F0 = 1− (Q0 + S0 +Q1 + S1). (A14)
Finally, using the expressions for mean number of surviving cells, Eq.(A7), and corresponding expression for the Fano
factor, Eq. (A12), for arbitrary p0, we get explicit expressions for the probability p0 and variance in initial M-type
cells σ2p0 . The resulting expressions are in terms of mean values 〈N〉0 (for p0 = 0) and 〈N〉1 (for p0 = 1) and the mean
and Fano factor for a given arbitrary p0, as shown in the main text.
Supplementary Material B: Analytical results in the growth phase
In this section, we provide details of the derivation of the moments for the surviving cell populations in the growth
phase.
First moments
Multiplying Eq. (1) by E or M and summing over all possible values of E and M, we obtain the evolution equations
for 〈E〉 = ∑EP (E,M, t) and 〈M〉 = ∑MP (E,M, t) :
∂〈E〉
∂t
= (kE − µE − kEM ) 〈E〉+ kME〈M〉,
∂〈M〉
∂t
= (kM − µM − kME) 〈M〉+ kEM 〈E〉, (B1)
These equations can be solved to get:
〈E〉 = 1
2α
[
(E0α− βE) exp
(
− t
2
(γ + α)
)
+ (E0α+ βE) exp
(
− t
2
(γ − α)
)]
,
〈M〉 = 1
2α
[
(M0α− βM ) exp
(
− t
2
(γ + α)
)
+ (M0α+ βM ) exp
(
− t
2
(γ − α)
)]
, (B2)
where E0 and M0 are initial values for the number of E-type and M -type cells respectively, and
γ = kEM + kME − kfE − kfM ,
α =
√
γ2 + 4
(
kME(k
f
E − kfM ) + (γ + kfM )kfM
)
,
βE = 2M0kME + E0
(
γ − 2(kEM − kfE)
)
,
βM = 2E0kEM +M0
(
γ − 2(kME − kfM )
)
(B3)
with
kfE = kE − µE , kfM = kM − µM , (B4)
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representing the effective birth rates for E-type and M -type cells, respectively. For the total population, N = E+M ,
using Eq. (B2), the mean 〈N〉 = 〈E〉+ 〈M〉 can then be written as:
〈N〉 =
(
E0(α− γ − 2kfE) +M0(α− γ − 2kfM )
2α
)
exp
(
− t
2
(γ + α)
)
+
(
E0(α+ γ + 2k
f
E) +M0(α+ γ + 2k
f
M )
2α
)
exp
(
− t
2
(γ − α)
)
. (B5)
Second moments
Using Eq. (1), we can write the evolution equation for
〈E2〉 =
∑
E2P (E,M, t), 〈M2〉 =
∑
M2P (E,M, t) and 〈EM〉 =
∑
EMP (E,M, t)
as:
∂〈E2〉
∂t
= (kE + µE + kEM )〈E〉+ kME〈M〉+ 2(kE − µE − kEM )〈E2〉+ 2kME〈ME〉,
∂〈M2〉
∂t
= (kM + µM + kME)〈M〉+ kEM 〈E〉+ 2(kM − µM − kME)〈M2〉+ 2kEM 〈ME〉,
∂〈ME〉
∂t
= −kME〈M〉 − kEM 〈E〉+ (kE + kM − µE − µM − kME − kEM )〈ME〉+ kME〈M2〉+ kEM 〈E2〉. (B6)
Eliminating variables in Eq. (B6), we obtain a single ODE for 〈E2〉,
d3〈E2〉
dt3
− c2 d
2〈E2〉
dt2
+ c1
d〈E2〉
dt
+ c0〈E2〉 = K(t), (B7)
where c0, c1 and c2 are functions of the model parameters
c2 = 3(kE + kM − kEM − kME − µE − µM ),
c1 = 2
[
k2E + k
2
EM + k
2
M − 2kMkME + kME2 − 4kMµE + 4kMEµe + µ2E − 2kmµM + 2kMEµM + 4µeµM + µ2M
+ 2kEM (−2kM + kME + µE + 2µM )− 2kE(kEM − 2kM + 2kME + µE + 2µM )] ,
c0 = 4(kE + kM − kEM − kME − µE − µM ) [kEMkM + kMµE − kMEµE − (kEM + µE)µM + kE(kME + µM − kM )] ,
(B8)
and K(t) is a known function in t:
K(t) = 1
2k2ME
[
(kM + µM + kME − kEM )〈M〉+ kEM
(
1− kE + µE + kEM
kME
)
〈E〉+ 2(kM − µM − kME)g(t)− dg(t)
dt
]
,
(B9)
with
g(t) = − 1
2k2ME
[
(kE + µE + kEM )
d〈E〉
dt
+ kME
d〈M〉
dt
]
+ 〈M〉+ kEM
kME
〈E〉+ kE + kM − µE − µM − kME − kEM
2k2ME
[(kE + µE + kEM )〈E〉+ kME〈M〉] . (B10)
The solution for 〈E2〉 in Eq. (B7) is:
〈E2〉 =
3∑
i=1
si exp[λit] +
3∑
i=1
exp[λit]
3λ2i − 2c2λi + c1
∫
K(t) exp(−λit)dt (B11)
where λi, i = 1, 2, 3 are the roots of
λ3 − c2λ2 + c1λ+ c0 = 0 (B12)
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and s1, s2, s3 are constants to be determined from the initial condition. Once we have obtained an expression for
〈E2〉, we can readily derive expressions for 〈M2〉 and 〈ME〉:
〈M2〉 = 1
2k2ME
[
d2〈E2〉
dt2
+ (3kEM + kME − 3kE − kM + 3µE + µM )d〈E
2〉
dt
+ 2 ((kE − kEM − µE)(kE − kEM + kM − kME − µE − µM )− kEMkME) 〈E2〉+ 2k2MEg(t)
]
,
〈ME〉 = 1
2kME
[
d〈E2〉
dt
− 〈M〉kME − 〈E〉(kE + kEM + µE)− 2(kE − kEM − µE)〈E2〉
]
. (B13)
Taking suitable initial conditions, we can find the constants s1, s2, s3 that will help specify the temporal evolution of
the second moments in terms of the model parameters.
